412 related articles for article (PubMed ID: 25023394)
21. Synthesis of a bi-functional dendrimer-based nanovehicle co-modified with RGDyC and TAT peptides for neovascular targeting and penetration.
Li J; Zhang X; Wang M; Li X; Mu H; Wang A; Liu W; Li Y; Wu Z; Sun K
Int J Pharm; 2016 Mar; 501(1-2):112-23. PubMed ID: 26828670
[TBL] [Abstract][Full Text] [Related]
22. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
23. A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration.
Xu X; Li J; Han S; Tao C; Fang L; Sun Y; Zhu J; Liang Z; Li F
Eur J Pharm Sci; 2016 Jun; 88():178-90. PubMed ID: 26965003
[TBL] [Abstract][Full Text] [Related]
24. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
[TBL] [Abstract][Full Text] [Related]
25. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound.
Deng Z; Xiao Y; Pan M; Li F; Duan W; Meng L; Liu X; Yan F; Zheng H
J Control Release; 2016 Dec; 243():333-341. PubMed ID: 27984104
[TBL] [Abstract][Full Text] [Related]
26. Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel.
Hu Q; Gao X; Gu G; Kang T; Tu Y; Liu Z; Song Q; Yao L; Pang Z; Jiang X; Chen H; Chen J
Biomaterials; 2013 Jul; 34(22):5640-50. PubMed ID: 23639530
[TBL] [Abstract][Full Text] [Related]
27. PEGylated Polyamidoamine dendrimer conjugated with tumor homing peptide as a potential targeted delivery system for glioma.
Jiang Y; Lv L; Shi H; Hua Y; Lv W; Wang X; Xin H; Xu Q
Colloids Surf B Biointerfaces; 2016 Nov; 147():242-249. PubMed ID: 27518456
[TBL] [Abstract][Full Text] [Related]
28. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
29. Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles.
Chu Y; Chen N; Yu H; Mu H; He B; Hua H; Wang A; Sun K
Int J Nanomedicine; 2017; 12():1353-1368. PubMed ID: 28260884
[TBL] [Abstract][Full Text] [Related]
30. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
[TBL] [Abstract][Full Text] [Related]
32. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
[TBL] [Abstract][Full Text] [Related]
33. Functionalized cell nucleus-penetrating peptide combined with doxorubicin for synergistic treatment of glioma.
Zhang L; Zhang Y; Tai L; Jiang K; Xie C; Li Z; Lin YZ; Wei G; Lu W; Pan W
Acta Biomater; 2016 Sep; 42():90-101. PubMed ID: 27370905
[TBL] [Abstract][Full Text] [Related]
34. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
[TBL] [Abstract][Full Text] [Related]
35. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.
Puig-Saus C; Rojas LA; Laborda E; Figueras A; Alba R; Fillat C; Alemany R
Gene Ther; 2014 Aug; 21(8):767-74. PubMed ID: 24942629
[TBL] [Abstract][Full Text] [Related]
36. Integrin-mediated active tumor targeting and tumor microenvironment response dendrimer-gelatin nanoparticles for drug delivery and tumor treatment.
Hu G; Zhang H; Zhang L; Ruan S; He Q; Gao H
Int J Pharm; 2015 Dec; 496(2):1057-68. PubMed ID: 26598487
[TBL] [Abstract][Full Text] [Related]
37. A Novel Strategy through Combining iRGD Peptide with Tumor-Microenvironment-Responsive and Multistage Nanoparticles for Deep Tumor Penetration.
Cun X; Chen J; Ruan S; Zhang L; Wan J; He Q; Gao H
ACS Appl Mater Interfaces; 2015 Dec; 7(49):27458-66. PubMed ID: 26633260
[TBL] [Abstract][Full Text] [Related]
38. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.
Zuo H
J Oncol; 2019; 2019():9367845. PubMed ID: 31346334
[TBL] [Abstract][Full Text] [Related]
39. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Schmithals C; Köberle V; Korkusuz H; Pleli T; Kakoschky B; Augusto EA; Ibrahim AA; Arencibia JM; Vafaizadeh V; Groner B; Korf HW; Kronenberger B; Zeuzem S; Vogl TJ; Waidmann O; Piiper A
Cancer Res; 2015 Aug; 75(15):3147-54. PubMed ID: 26239478
[TBL] [Abstract][Full Text] [Related]
40. Novel, nano-sized, liposome-encapsulated polyamidoamine dendrimer derivatives facilitate tumour targeting by overcoming the polyethylene glycol dilemma and integrin saturation obstacle.
Li G; Song YZ; Huang ZJ; Chen K; Chen DW; Deng YH
J Drug Target; 2017 Sep; 25(8):734-746. PubMed ID: 28452577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
